Lisa Olson - May 17, 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Title: Head of Research and Chief Scientific Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Lisa Olson
Stock symbol
DNTH
Transactions as of
May 17, 2022
Transactions value $
$0
Form type
4
Date filed
5/19/2022, 04:24 PM
Previous filing
Feb 17, 2022
Next filing
Aug 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Award $0 +50K $0.00 50K May 17, 2022 Common Stock 50K $1.18 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022.

Remarks:

Title: Head of Research and Chief Scientific Officer